Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...
Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file ...
Diabetes poses a significant risk to bone health, leading to decreased bone mineral density and increased fracture ...
Amgen said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, a day after ...
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...
Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...
CEO Bob Bradway said Amgen is "well advanced" in preparing to launch a Phase 3 testing round of MariTide in order to have ...
University of Alberta-led researchers, including the developers and promoters of the Fracture Risk Assessment Tool (FRAX), ...
According to the International Osteoporosis Foundation, osteoporosis is the most common bone disease. It affects one in five ...
Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...